MeSH D001714 - bipolar disorder
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000068105:Bipolar and related disorders
0 Companies
0 Drugs
Success rate
D001714:Â
Bipolar disorder
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AbbVie | Cariprazine | Vraylar | 2028-12-16 | 2015-09-17 | $3,132 M | Q4/23-Q3/24 |
| Valproic acid | Depakene |  | 1982-01-01 |  |  | |
| Able Laboratories | Lithium | Lithium |  | 2001-09-27 |  |  |
| Abon Pharmaceuticals | Gabapentin | Gabapentin |  | 2024-09-09 |  |  |
| Accord Healthcare | Aripiprazole | Aripiprazole Accord |  | 2015-11-15 |  |  |
| Clozapine | Clozapine |  | 2015-11-25 |  |  | |
| Lurasidone | Lurasidone |  | 2019-01-03 |  |  | |
| Quetiapine | Quetiapine |  | 2016-11-01 |  |  | |
| Topiramate | Topiramate |  | 2009-03-27 |  |  | |
| Acella Pharmaceuticals | Gabapentin | Gabapentin |  | 2012-05-01 |  |  |
| ACRAF | Lurasidone | Latuda |  | 2014-03-21 |  |  |
| Ajanta Pharma | Lamotrigine | Lamotrigine |  | 2021-01-19 |  |  |
| Olanzapine | Olanzapine |  | 2017-05-30 |  |  | |
| Risperidone | Risperidone |  | 2011-08-24 |  |  | |
| Carbamazepine | Carbamazepine |  | 2023-03-24 |  |  | |
| Topiramate | Topiramate |  | 2023-08-15 |  |  | |
| Paliperidone | Paliperidone |  | 2024-06-26 |  |  | |
| Alembic Pharmaceuticals | Asenapine | Asenapine |  | 2020-12-10 |  |  |
| Lamotrigine | Lamotrigine |  | 2011-01-13 |  |  | |
| Lithium | Lithium |  | 2009-01-12 |  |  | |
| Lurasidone | Lurasidone |  | 2021-05-13 |  |  | |
| Quetiapine | Quetiapine |  | 2014-10-28 |  |  | |
| Paliperidone | Paliperidone |  | 2024-09-26 |  |  | |
| Alkem Laboratories | Gabapentin | Gabapentin |  | 2010-12-17 |  |  |
| Lamotrigine | Lamotrigine |  | 2013-06-14 |  |  | |
| Olanzapine | Olanzapine |  | 2015-10-20 |  |  | |
| Quetiapine | Quetiapine |  | 2013-02-12 |  |  | |
| Lurasidone | Lurasidone |  | 2022-12-13 |  |  | |
| Topiramate | Topiramate |  | 2023-06-20 |  |  | |
| Alkermes | Olanzapine, Samidorphan | Lybalvi | 2025-11-23 | 2021-05-28 | $259.273 M | Q4/23-Q3/24 |
1
2
3
4
5
6
...
15
>
Clinical Trials
Historical Success Rate
Phase 1
85%40/47
Phase 2
51%45/88
Phase 3
69%65/94
Approved: 24Overall Success rate: 30%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
10
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use